Study by Kikuchiet al. 2013 tried to address this cut-off issue found that when we set the cut-off of p53 immunoreactivity into ≥50%, then it could be helpful to predict clinical behavior in Luminal Breast Cancer, especially Luminal B type (p<0.0001).96 The gene discussed is TP53; the disease is breast cancer.